Page 4,935«..1020..4,9344,9354,9364,937..4,9404,950..»

U.S. Veterans Administration Fails to Provide Effective Treatment to Over 200,000 Veterans Suffering with Traumatic …

Posted: Published on September 4th, 2013

(PRWEB) September 04, 2013 In a study commissioned by the Veterans Administration, the Rand Corporation interviewed thousands of veterans from Iraq and Afghanistan and estimated 18% suffer from PTSD and 19% suffer from traumatic brain injury (TBI). Yet according to the Defense and Brain Injury Center, 266,810 soldiers were diagnosed with PTSD from 2000 through 2012; yet only 54,000 were diagnosed with TBI during this period. "Soldiers returning from Iraq and Afghanistan with TBI are being under-diagnosed and often ineffectively treated. This under-diagnosis and ineffective treatment results in increased levels of chronic pain, substance abuse, depression and suicide among returning warriors," stated Rolando Hernandez M.D. neurosurgeon for Neurological Wellness Center. A study published in 2012 in the journal CNS Drugs** involving persons with TBI treated with perispinally administered etanercept (Enbrel) found that 75.0% reported a reduction in chronic pain, 87.5% exhibited a reduction of cognitive impairment, and 80.0 exhibited a reduction of psychological impairment. The authors note: Rapid improvement of mood, affect, and attitude was commonly observed. Patients and families commonly reported improvement of depression, anxiety, irritability, motivation, initiative, hopefulness and a return to pre-TBI personality (his personality is back) and a sense of humor. An examination of the Veterans … Continue reading

Posted in Brain Injury Treatment | Comments Off on U.S. Veterans Administration Fails to Provide Effective Treatment to Over 200,000 Veterans Suffering with Traumatic …

Brain injury centre saved me from depression

Posted: Published on September 4th, 2013

Cambridge News Follow us on Wednesday 4 Sep 2013 3:36 PM Written byLIZZY BUCHAN A brain injury survivor has said he is a different person after a rehabilitation centre saved him from depression. Tim Lodge, of Burwell, suffered a serious brain injury after falling off his bike in 2009 and the incident left his so low that he attempted suicide. In a new book called Life After Brain Injury: Survivors Stories, the 52-year-old credits the work of the Oliver Zangwill Centre (OZC), at the Princess of Wales Hospital, in Ely, for helping him to rebuild his life. He said: I was riding home one evening from my job as a design engineer at Marshalls, when I got knocked off my bike. I didnt think Id been knocked unconscious and I had no obvious serious injuries, so after I was checked over at the hospital I was sent home. I just thought I might need a few days off and then go back to work. Tim began to suffer from headaches and his head swelled up so he went to his doctor again. Tests then confirmed he had a serious brain injury. After recommendations that he attend the OZC, Tim admitted … Continue reading

Posted in Brain Injury Treatment | Comments Off on Brain injury centre saved me from depression

Snowboarding Star, Traumatic Brain Injury Survivor Kevin Pearce To Speak At Braintree Rehabilitation Hospital's 34th …

Posted: Published on September 4th, 2013

BRAINTREE, Mass., Sept.4, 2013 /PRNewswire/ --Snowboarding star and traumatic brain injury survivor Kevin Pearce will be the keynote speaker at Braintree Rehabilitation Hospital's 34th Annual Neurorehabilitation Conference, to be held October 26 and 27 at the Hyatt Regency Hotel in Cambridge, Massachusetts. One of the longest running and most prestigious conferences of its kind, this event brings together thought leaders in traumatic brain injury, stroke and other neurologic disorders to present the most recent research and clinical findings and discuss their impact on patient treatment. Pearce, son of internationally renowned glass artist Simon Pearce, was considered a favorite to make the U.S. Olympic Team for the 2010 Vancouver Games when he sustained a traumatic brain injury during a halfpipe training run which ended his career. His remarkable story was chronicled in the documentary, "The Crash Reel." Today, as a sports commentator and an advocate for the prevention of traumatic brain injuries, he will speak about his life-altering experience and subsequent neurorehabilitation. "Kevin Pearce's experience will enlighten us in our understanding of brain injury, recovery and how it affects the lives of survivors and their families," said Dr. Douglas Katz, Medical Director of the nationally recognized Acquired Brain Injury Program at … Continue reading

Posted in Brain Injury Treatment | Comments Off on Snowboarding Star, Traumatic Brain Injury Survivor Kevin Pearce To Speak At Braintree Rehabilitation Hospital's 34th …

Today’s hormone therapy progesterone could be tomorrow’s treatment for traumatic brain injury

Posted: Published on September 4th, 2013

Put aside what you think you know about the sex hormone progesterone and consider this: It could be the foundation for a drug treatment for traumatic brain injury. BHR Pharma said Tuesday that its completed enrollment in a Phase III safety and efficacy study of its progesterone formulation, BHR-100, as a neuroprotective agent for people who experience moderate to severe traumatic brain injury. Started back in June of 2010, the SyNAPSe trial has extended the experimental therapy to nearly 1,200 TBI patients at 150 participating sites in the U.S., Israel, Argentina and 18 other countries in Europe and Asia. Patients in the trial received a five-day continuous IV infusion of progesterone beginning within eight hours of injury, the company says. The primary goal is to see improved outcomes six months after injury using the Glasgow Outcome Scale. Results for the trial, which has been done in conjunction with the American Brain Injury Consortium and the European Brain Injury Consortium, are expected in May 2014. A company representative could not be reached for additional comments on Tuesday. Although its most commonly known for its role in regulating certain functions of ovulation and menstruation in women, progesterone therapy has also been found … Continue reading

Posted in Brain Injury Treatment | Comments Off on Today’s hormone therapy progesterone could be tomorrow’s treatment for traumatic brain injury

Jeryl L. Hilleman Joins Ocera Therapeutics as Chief Financial Officer

Posted: Published on September 4th, 2013

SAN DIEGO, Sept. 3, 2013 (GLOBE NEWSWIRE) -- Ocera Therapeutics (OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Jeryl L. Hilleman has been appointed chief financial officer effective September 3, 2013. Ms. Hilleman will replace Dana McGowan who will continue with the company during a transition period in which the company plans to move its headquarters to Northern California. "I am very pleased that an executive with Jeri's skills, global experience and proven expertise is joining our senior management team," said Linda Grais, M.D., president and chief executive officer of Ocera. "Her extensive public company experience, both in and outside of the biotech industry, combined with her operational leadership, will be invaluable as we execute on our immediate business priority to initiate a Phase 2b clinical trial of OCR-002 for the treatment of acute hepatic encephalopathy. I would also like to thank Dana McGowan for her many contributions and years of dedication to Ocera." "Ocera has the potential to transform both acute and chronic treatment of critical liver conditions, with significant potential to save lives," said Jeri Hilleman. "The opportunity to join Ocera to help realize this potential is exciting and … Continue reading

Posted in MS Treatment | Comments Off on Jeryl L. Hilleman Joins Ocera Therapeutics as Chief Financial Officer

Apitope releases positive results from Phase I clinical study of multiple sclerosis drug

Posted: Published on September 4th, 2013

PBR Staff Writer Published 03 September 2013 Drug discovery and development firm Apitope has completed its second Phase I clinical trial of ATX-MS-1467 with positive results. When patients with relapsing multiple sclerosis were treated with intradermal injection of ATX-MS-1467, the MRI results showed a decrease in the number of contrast-enhancing brain lesions (CEL). The positive results allow Merck Serono with whom Apitope is developing ATX-MS-1467 to advance its Phase II plans. Apitope CEO Keith Martin said," The results of this trial in patients with relapsing MS continue to build on the positive data from our first study and provide further clinical support for the Apitope approach to the treatment of serious autoimmune conditions." Apitope's ATX-MS-1467 treatment is aimed at working with the immune system to treat the underlying cause of disease and restoring immunological balance, rather than just treating the symptoms or suppressing the complete immune system. Apitope CSO and founder David Wraith said antigen specific immunotherapy is designed to correct the immunological imbalance that causes autoimmune disease without inducing the non-specific immune suppression that so frequently causes unacceptable side effects. "Up to now this approach has been shown to be highly effective in experimental models but has been slow … Continue reading

Posted in MS Treatment | Comments Off on Apitope releases positive results from Phase I clinical study of multiple sclerosis drug

Apitope Announces Positive Results from Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis

Posted: Published on September 4th, 2013

BRISTOL, Englad & HASSELT, Belgium--(BUSINESS WIRE)-- Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announced completion with positive results of its second Phase I clinical trial of ATX-MS-1467. Examination of the MRI results (new Gd and total Gd enhancing lesions) demonstrated a significant decrease in the number of contrast-enhancing brain lesions (CEL) in patients with relapsing multiple sclerosis treated by intradermal injection of ATX-MS-1467. The same effect was not seen in the subcutaneously dosed group. These encouraging results will now need confirmation in appropriate Phase II trials. Completion of the study together with these positive MRI-based data allows Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, with whom Apitope is developing ATX-MS-1467, to develop plans for Phase II onwards. Dr. Keith Martin, CEO of Apitope stated: We are pleased to have successfully completed a challenging clinical trial with positive results. The results of this trial in patients with relapsing MS continue to build on the positive data from our first study and provide further clinical support for the Apitope approach to the treatment of serious autoimmune conditions. Prof David Wraith, Apitopes CSO and Founder added: Antigen specific immunotherapy is … Continue reading

Posted in MS Treatment | Comments Off on Apitope Announces Positive Results from Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis

Researchers discover potential epilepsy drug using zebrafish

Posted: Published on September 4th, 2013

An antihistamine used to treat itching may be the key to preventing seizures in children with a rare, yet severe form of epilepsy known as Dravet Syndrome. The discovery was made by screening hundreds of government-approved drugs in animals with the same genetic mutation as children with the disorder. But instead of using rodents the typical animal model for drug screenings researchers used an unlikely test subject for their experiment: zebrafish. According to the researchers, the antihistamine known as clemizole could be the first line approach for reducing the effects of Dravet Syndrome a condition with very limited treatment options. Dravet Syndrome is a catastrophic form of childhood epilepsy, and it often leads to severe symptoms and death, Scott Baraban, a professor of neurological surgery at the University of California, San Francisco and William K. Bowes Jr. Endowed Chair in neuroscience research, told FoxNews.com. Within the first year of life, children will start to have seizures and have several hundred per day. Theyll have delays in speech, cognitive problems, ataxia, which is trouble standing And while there are drugs that are given that reduce the effects, there arent too many treatment options for these kids. Baraban first pioneered the idea … Continue reading

Comments Off on Researchers discover potential epilepsy drug using zebrafish

Women at a HEALTHY weight are more likely to get breast cancer when using HRT than overweight women

Posted: Published on September 4th, 2013

White and Hispanic women are at greater risk than black women are Women with dense breasts are also more likely to develop breast cancer Findings suggest that some women could take HRT without experiencing an increased risk of breast cancer By Emma Innes PUBLISHED: 15:07 EST, 3 September 2013 | UPDATED: 15:07 EST, 3 September 2013 50 shares 24 View comments Women who are a healthy weight are more likely to get breast cancer when using hormone replacement therapy, according to a new study Women who are a healthy weight are more likely to get breast cancer when using hormone replacement therapy, according to a new study. Breast cancer has long been associated with the use of hormone replacement therapy (HRT) during the menopause. Scientists say this risk is increased among certain groups - including white women with a healthy body mass index (BMI). Read the rest here: Women at a HEALTHY weight are more likely to get breast cancer when using HRT than overweight women … Continue reading

Posted in Hormone Replacement Therapy | Comments Off on Women at a HEALTHY weight are more likely to get breast cancer when using HRT than overweight women

Association between hormone replacement therapy use and breast cancer risk varies

Posted: Published on September 4th, 2013

Sep. 3, 2013 Breast cancer risk associated with use of hormone replacement therapy (HRT) among postmenopausal women was variable when analyzed by race/ethnicity, body mass index (BMI), and breast density, according to a new study published September 3 in the Journal of the National Cancer Institute. Studies have reported HRT use is associated with an increase in breast cancer risk. However, differential risks by BMI and breast density have been reported. Also, studies on the effect of HRT use on breast cancer risk among black women have reported inconsistent results. Ningqi Hou, M.H.S., Ph.D., from the University of Chicago, in Chicago, IL, and colleagues analyzed 1,642,824 screening mammograms, which included 9,300 breast cancer cases, from postmenopausal women from the Breast Cancer Surveillance Consortium, a US registry of mammography screening. Data on HRT use were analyzed by race/ethnicity, age, BMI, and breast density using statistical methods to accommodate missing information on HRT use and other covariables. Statistically significant interactions between HRT use and each covariable were calculated. A greater than 20% increased risk in breast cancer was associated with HRT use among white women and Hispanic women, but not black women. HRT use was more strongly associated with breast cancer risk … Continue reading

Posted in Hormone Replacement Therapy | Comments Off on Association between hormone replacement therapy use and breast cancer risk varies

Page 4,935«..1020..4,9344,9354,9364,937..4,9404,950..»